Nektar Therapeutics (NASDAQ:NKTR) has been assigned a $54.00 target price by equities research analysts at HC Wainwright in a report released on Friday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential downside of 9.62% from the company’s previous close.
NKTR has been the subject of a number of other research reports. BidaskClub cut Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, June 28th. Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a report on Monday, July 16th. Piper Jaffray Companies set a $125.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a report on Wednesday. ValuEngine lowered Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 26th. Finally, Mizuho reissued a “buy” rating and set a $103.00 price target on shares of Nektar Therapeutics in a report on Thursday. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $77.67.
Nektar Therapeutics traded up $0.38, reaching $59.75, during mid-day trading on Friday, Marketbeat reports. 2,972,194 shares of the stock traded hands, compared to its average volume of 2,068,420. The stock has a market cap of $10.18 billion, a PE ratio of 11.97 and a beta of 2.08. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.03 and a current ratio of 19.67. Nektar Therapeutics has a 12-month low of $17.51 and a 12-month high of $111.36.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported $5.33 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.11. The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Nektar Therapeutics had a return on equity of 174.70% and a net margin of 65.69%. Nektar Therapeutics’s revenue for the quarter was up 3043.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.39) earnings per share. sell-side analysts predict that Nektar Therapeutics will post 3.41 EPS for the current fiscal year.
In other news, CEO Howard W. Robin sold 12,791 shares of the company’s stock in a transaction dated Wednesday, May 16th. The stock was sold at an average price of $83.39, for a total value of $1,066,641.49. Following the completion of the transaction, the chief executive officer now owns 224,356 shares of the company’s stock, valued at $18,709,046.84. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Stephen K. Doberstein sold 3,435 shares of the company’s stock in a transaction dated Wednesday, May 16th. The stock was sold at an average price of $83.39, for a total value of $286,444.65. Following the completion of the transaction, the senior vice president now directly owns 63,959 shares of the company’s stock, valued at approximately $5,333,541.01. The disclosure for this sale can be found here. Insiders have sold 214,394 shares of company stock valued at $11,846,101 in the last three months. 4.31% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Asset Management One Co. Ltd. bought a new position in shares of Nektar Therapeutics in the first quarter worth about $110,000. Daiwa Securities Group Inc. bought a new position in shares of Nektar Therapeutics in the first quarter worth about $111,000. We Are One Seven LLC bought a new position in shares of Nektar Therapeutics in the first quarter worth about $118,000. Harbor Advisors LLC bought a new position in shares of Nektar Therapeutics in the first quarter worth about $213,000. Finally, Canandaigua National Bank & Trust Co. bought a new position in shares of Nektar Therapeutics in the first quarter worth about $219,000. 91.18% of the stock is owned by hedge funds and other institutional investors.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Featured Story: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.